LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 studyBenjamin Musher, Angelica Loskog, Salmaan Jawaid et al.|The Lancet Oncology|2024Cited by 64
A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.Benjamin Musher, Angelica Sara Ingrid Loskog, Brandon G. Smaglo et al.|Journal of Clinical Oncology|2022Cited by 19
A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS).Brandon G. Smaglo, Ann M. Leen, Benjamin Musher et al.|Journal of Clinical Oncology|2020Cited by 15